Sees FY23 adjusted EBITDA $75M-$125M vs. $26.1M in FY22.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EBS:
- Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
- Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
- Emergent announces FDA advisory committees vote in favor of OTC Narcan
- FDA Joint Committee Meeting
- Emergent Surges after Selling its Travel Health Business for $380 Million